Acorda Therapeutics Inc


Acorda Therapeutics Inc (ACOR) and Finish Line Inc (FINL) Fell Off a Cliff; Analysts Look for Survivors

Can These Biotech Stocks Recover from an FDA Setback and a Stark 2Q Preliminary Earnings Stumble?

Acorda Therapeutics Inc (ACOR) Shares Are Getting Hammered; Here’s Why

Acorda Therapeutics Inc (NASDAQ:ACOR) stock got hammered 26% Tuesday morning as Wall Street came down hard on the company. The reason?

Acorda Therapeutics Inc (ACOR): Key Takeaways from CVT-301 Presentation at MDS

Yesterday afternoon, Acorda Therapeutics Inc (NASDAQ:ACOR) presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically …

Acorda Therapeutics Inc (ACOR) Is Undervalued for CVT-301’s Potential: Cowen

Acorda Therapeutics Inc (NASDAQ:ACOR) shares climbed nearly 10% to $16.80 in after-hours trading Monday, after the drug maker announced that its Parkinson’s disease drug, …

Acorda Therapeutics Inc (ACOR) Faces Clear Setback With Unfavorable Ampyra Ruling

On Friday, Acorda Therapeutics Inc (NASDAQ:ACOR) was met with misfortune after a district judge invalidated four patents for its multiple sclerosis drug Ampyra, …

Friday’s Market Insights: Akari Therapeutics PLC (ADR) (AKTX), Acorda Therapeutics Inc (ACOR), BlackBerry Ltd (BBRY)

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) shares skyrocketed over 40% in Friday’s trading session, after the company announced that the FDA has designated as …

J.P. Morgan Provides Thoughts On Acorda Therapeutics Inc (ACOR)

Acorda Therapeutics Inc (NASDAQ:ACOR) shares rose 13% in Thursday’s trading session, after the drug maker announced topline data for CVT-301, an inhaled levodopa therapy …

Stock Update (NASDAQ:ACOR): Here’s Why Acorda Therapeutics Inc Shares Are Falling 10% Today

Acorda Therapeutics Inc (NASDAQ:ACOR) investors are having a rough morning, after the drug maker announced that it plans to discontinue the development of Ampyra …

Cowen Cuts Price Target for Acorda Therapeutics Inc (ACOR) Following Clinical Trial Setback

In a research report published Friday, Cowen analyst Phil Nadeau reiterated an Outperform rating on shares of Acorda Therapeutics Inc (NASDAQ:ACOR), while reducing the price …

Evercore Comments on Acorda Therapeutics Inc (ACOR) as it Ends Development of Epilepsy Drug

Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) are down nearly 5% in early trading Friday, after the drug maker announced that it will discontinue the development …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts